Evidence map›Paper›PMID 32942740›Full record

ArticleJournal of clinical medicine2020

Increased Antioxidant Capacity and Pro-Homeostatic Lipid Mediators in Ocular Hypertension-A Human Experimental Model.

Mia Langbøl, Sarkis Saruhanian, Thisayini Baskaran, Daniel Tiedemann, Zaynab A Mouhammad, Anne Katrine Toft-Kehler, Bokkyoo Jun, Rupali Vohra, Nicolas G Bazan, Miriam Kolko

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Higher vitamin BFrontiers in nutrition · 2024
    Article
  4. Distinct Metabolic Profiles of Ocular Hypertensives in Response to Hypoxia.International journal of molecular sciences · 2023
    Article
  5. Review
  6. Oxidative Stress in Optic Neuropathies.Antioxidants (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Mia LangbølDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0003-4107-8990
Sarkis SaruhanianDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0001-7143-7654
Thisayini BaskaranDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Daniel TiedemannDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Zaynab A MouhammadDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Anne Katrine Toft-KehlerDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Bokkyoo JunNeuroscience Center of Excellence, Louisiana State University Health New Orleans, New Orleans, LA 70112, USA.
Rupali VohraDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Nicolas G BazanNeuroscience Center of Excellence, Louisiana State University Health New Orleans, New Orleans, LA 70112, USA.
Miriam KolkoDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0001-8697-0734
University of Copenhagen · DKLouisiana State University Health Sciences Center New Orleans · US

Funding

Fight for Sight, Denmark 113846Fight for Sight, Denmark 114065Fight for Sight, Denmark 115774Jørgen Bagenkop Nielsen's Myopi-Foundation 117138Jørgen Bagenkop Nielsen's Myopi-Foundation 117139Lion's Prize No Grant NumberSynoptik Foundation 117140
6 · The paper itself

Abstract

The main risk factor for primary open-angle glaucoma (POAG) is increased intraocular pressure (IOP). It is of interest that about half of the patients have an IOP within the normal range (normal-tension glaucoma, NTG). Additionally, there is a group of patients with a high IOP but no glaucomatous neurodegeneration (ocular hypertension, OHT). Therefore, risk factors other than IOP are involved in the pathogenesis of glaucoma. Since the retina has a very high oxygen-demand, decreased autoregulation and a fluctuating oxygen supply to the retina have been linked to glaucomatous neurodegeneration. To assess the significance of these mechanisms, we have utilized a human experimental model, in which we stress participants with a fluctuating oxygen supply. Levels of oxidative stress molecules, antioxidants, and lipid mediators were measured in the plasma. Patients with NTG, OHT, and control subjects were found to have similar levels of oxidative stress markers. In contrast, patients with OHT had a higher level of total antioxidant capacity (TAC) and pro-homeostatic lipid mediators. Thus, we suggest that OHT patients manage fluctuating oxygen levels more efficiently and, thus, are less susceptible to glaucomatous neurodegenerations, due to enhanced systemic antioxidant protection.

Indexed as

antioxidant capacityhydroxydocosahexaenoic acidshydroxyeicosatetraenoic acidshypoxialipidomicsnormal-tension glaucomaocular hypertensionoxidative stresspro-homeostatic lipid mediators

Identifiers

PMID32942740
PMCPMC7563216
OpenAlexW3084462935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.